RxDoctor Payments Data

Vibha Lama

Pulmonary Disease · Ann Arbor, MINPI 1255413167

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Mallinckrodt Hospital Products Inc. accounts for 85.2% of it on its own, with 1 other manufacturer making up the rest. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,791in general payments, 2019–2025

Across 9 payments — averaging $2865.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$22K
  • Jazz Pharmaceuticals Inc.$4K
$187,440in research payments, 2019–2025

Across 3 payments — averaging $62,480 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$174K
  • AstraZeneca$13K

What the payments were for

  • Consulting fees$14,29555%
  • Travel & lodging$11,37544%
  • Food & beverage$1210%

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,791 in reported general payments places this provider in the 90th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$3,897
Medicare patients
14
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →